NEW YORK, Oct. 29, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Consensus Outlook: Multiple Sclerosis
http://www.reportlinker.com/p01006956/Consensus-Outlook-Multiple-Sclerosis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.4 billion in 2012 to $18.3 billion in 2017. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.
Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:
Key Benefits
Multiple Sclerosis: On the cusp of a treatment revolution will allow you to
Reasons to Buy this Report
Forecast analysis report and data model
The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.
FirstWord's MS forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters:
Event Assessments
Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event's occurrence.
Whether it's a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.
Methodology
For each Therapy Trends report, FirstWord analysts produce a data analysis module, a Consensus Outlook, which provides annual historical and forecast, product-level sales data. Historical sales data is derived from company information, while the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.
Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections – produced either internally or by other third parties – can be assessed.
Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a 'consensus calendar' of events designed to help inform FirstWord clients on how the market will evolve.
Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a 'bottom-up' forecasting methodology) and the strategic protocols being pursued by company management.
To order this report: Consensus Outlook: Multiple Sclerosis
http://www.reportlinker.com/p01006956/Consensus-Outlook-Multiple-Sclerosis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article